Jierou Lin's research while affiliated with Guangdong Pharmaceutical University and other places

What is this page?


This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.

It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.

If you're a ResearchGate member, you can follow this page to keep up with this author's work.

If you are this author, and you don't want us to display this page anymore, please let us know.

Publications (1)


This diagram depicts the expulsion of cells by efflux transporters, including P-gp, BCRP, and MRP-1. Other mechanization includes drug inactivation by increasing the expression of enzymes that metabolize drugs and the development of resistance. Cells can develop resistance by changing the target of a drug, thus disabling the drug. Drug isolation into lysosomes can cause drug inactivation and cause cancer cells to acquire resistance. Drugs inhibit cell apoptosis and produce drug resistance by interfering with the genetic cycle of cells. BCRP: Breast cancer resistance protein; Bcl-2: B-cell leukemia protein 2; MRP: multidrug resistance-related protein; P-gp: p-glycoprotein.
The application of nano-loaded drug system in anti-drug resistance of tumor cells. The advantage of EPR effects could increase the aggregation of drugs in cells, surface-modified antibodies, aptamers, and folic acid can increase the targeting effects, and drugs can also be encased in nanoparticles to escape the recognition of efflux proteins. CQDs: Carbon quantum dots; EPR: enhanced penetration and retention; GO: graphene oxide; HA: hyaluronic acid; IONP: iron oxide nanoparticle; MSN: mesoporous silica nanoparticle; NPs: nanoparticles; β-CD: β-cyclodextrin.
Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system
  • Literature Review
  • Full-text available

June 2023

·

16 Reads

·

10 Citations

Cancer Drug Resistance

Xiangyu Sun

·

Ping Zhao

·

Jierou Lin

·

[...]

·

Jianliang Shen

Cancer is currently one of the most intractable diseases causing human death. Although the prognosis of tumor patients has been improved to a certain extent through various modern treatment methods, multidrug resistance (MDR) of tumor cells is still a major problem leading to clinical treatment failure. Chemotherapy resistance refers to the resistance of tumor cells and/or tissues to a drug, usually inherent or developed during treatment. Therefore, an urgent need to research the ideal drug delivery system to overcome the shortcoming of traditional chemotherapy. The rapid development of nanotechnology has brought us new enlightenments to solve this problem. The novel nanocarrier provides a considerably effective treatment to overcome the limitations of chemotherapy or other drugs resulting from systemic side effects such as resistance, high toxicity, lack of targeting, and off-target. Herein, we introduce several tumor MDR mechanisms and discuss novel nanoparticle technology applied to surmount cancer drug resistance. Nanomaterials contain liposomes, polymer conjugates, micelles, dendrimers, carbon-based, metal nanoparticles, and nucleotides which can be used to deliver chemotherapeutic drugs, photosensitizers, and small interfering RNA (siRNA). This review aims to elucidate the advantages of nanomedicine in overcoming cancer drug resistance and discuss the latest developments.

Download
Share

Citations (1)


... Furthermore, there are many new drugs to control cancer by influencing circadian rhythm [102]. Drug delivery systems also appear as an anti-tumor way [103,104]. To accommodate the human's circadian rhythm, researchers are developing circadian drug delivery systems. ...

Reference:

Chronobiology of the Tumor Microenvironment: Implications for Therapeutic Strategies and Circadian-Based Interventions
Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system

Cancer Drug Resistance